First-time U.S. Con completed the Pre-A round of financing to accelerate the market transformation of tumor molecular diagnostic products.

Recently, Shenzhen Yousankang Biotech Co., Ltd. (hereinafter referred to as "YouSankang") announced the completion of the Pre-A round of financing, led by Shenzhen Innovation Investment Group Co., Ltd., Shenzhen Talent Innovation and Entrepreneurship No. 1 Equity Investment Fund (Limited Partnership) and Shenzhen Red Earth Angel Equity Investment Fund Partnership (Limited Partnership) with investment.
It is learned that YousanKang was founded in 2015, by the Sino-AMERICAN team of scientists and entrepreneurs co-founded, the company mainly focuses on in-body molecular diagnosis, product development, production, marketing and services as a whole, has built a complete industrial chain in the field of molecular diagnostics.
has now declared 35 patents for inventions and utility models and granted 21 patents.
specifically, YouSankang's business includes in-body diagnostic reagents, medical test analyzers, medical testing services three major areas.
, in-body diagnostic reagent products are based on three technical platforms: genetic testing, immunotesta and cytology, covering early tumor screening, tumor-based diagnosis, infectious diseases, cardiovascular and metabolic diseases.
At present, Yousankang to early cancer screening and individual diagnosis as the main direction, has successfully developed a suitable for plasma ctDNA, tumor tissue gene mutation and ctDNA methylation molecular detection of the initial product line, product detection sensitivity of 3 copies, compared with existing clinical applications of detection technology, with simple, fast, low cost, easy to promote and other advantages.
addition to technology and products, Yousankang also has a professional research and development center and international standards of GMP plant.
its research and development center is located in Shenzhen Longhua Mission Hills High-tech Industrial Park, under the U.S. Sankang medical inspection occupied by 1500 square meters, equipped with international advanced, comprehensive, diversified testing platform.
In addition, it is worth noting that, in response to the outbreak of the new crown, around January this year, Yousankang also set up the first project emergency technical team, successfully developed a new coronavirus (2019-nCoV) nucleic acid testing kit (PCR fluorescent probe method).
the product uses the latest core technology RNA one-step technology platform, suitable for sputum, swabs, anti-bubble lotion and other sample types, can be used for the identification of early infection, virus detection.
For this financing, YouSankang co-founder and CEO Dr. Yu Dehua said: Since its inception, YouSankang has been committed to building Best-in-Class and First-in-Class innovative molecular diagnostic products research and development strategy, has developed and completed a significant differentiation and competitive advantage of more than a dozen molecular diagnostic products.
success of this financing will provide a strong guarantee for the marketing and sale of registered products and the rapid advance of clinical trials of innovative products.
For investment in YouSankang, Shenzhen Innovation Investment Group Executive General Manager Meng Jianbin said: Yousan Kang founding team has been engaged in overseas multinational pharmaceutical companies for many years of research and development work, experienced technical experts, but also in the domestic well-known listed companies in charge of operating work, outstanding business performance of managers, has a good complementarity and industry reputation.
company's research and development pipeline around the clinical pain point of tumor liquid biopsy, the industrialization path is clear, the product advantage is obvious, the market prospects are broad, look forward to also firmly believe that YouSankang can achieve the established goals.
paint leaf green source: E!-- content display ends -- !-- determine whether the login ends.